Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16858613 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 | |
| SCHEMBL16584512 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 | |
| SCHEMBL14777584 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 | |
| SCHEMBL235095 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 | |
| SCHEMBL18339530 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 | |
| SCHEMBL360532 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 | |
| SCHEMBL19357245 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 | |
| SCHEMBL237210 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 | |
| SCHEMBL9056653 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 | |
| SCHEMBL976649 | 1.00 | CES2 (0.53) | CES2MEN1KMT2AKDM4EDUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200261596-A1 | Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same | PFIZER INC. (US) | 2020-08-20 | — | — | US | claimed |
| EP-3528794-A1 | THERAPEUTIC PARTICLES WITH PEPTIDE BORONIC ACID OR BORONATE ESTER COMPOUNDS AND METHODS OF MAKING AND USING SAME | Pfizer Inc (US) | 2019-08-28 | — | — | EP | claimed |
| WO-2018073790-A1 | THERAPEUTIC PARTICLES WITH PEPTIDE BORONIC ACID OR BORONATE ESTER COMPOUNDS AND METHODS OF MAKING AND USING SAME | PFIZER INC. (US) | 2018-04-26 | — | — | WO | claimed |
| EP-3220741-A1 | COMPOSITION AND KITS FOR INHIBITION OF PATHOGENIC MICROBIAL INFECTION AND METHODS OF USING THE SAME | Rochal Industries, LLC (US) | 2017-09-27 | — | — | EP | claimed |
| WO-2016054021-A1 | COMPOSITION AND KITS FOR INHIBITION OF PATHOGENIC MICROBIAL INFECTION AND METHODS OF USING THE SAME | ROCHAL INDUSTRIES, LLC (US) | 2016-04-07 | — | — | WO | claimed |
| WO-2025037261-A1 | METHODS OF PREVENTING OR TREATING LIVER DISEASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2025-02-20 | — | — | WO | disclosed |
| CN-116829203-A | Coated medical product | 亨莫特克股份公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-116710156-A | Coated medical product | 亨莫特克股份公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20200261596-A1 | Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same | PFIZER INC. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-3528794-A1 | THERAPEUTIC PARTICLES WITH PEPTIDE BORONIC ACID OR BORONATE ESTER COMPOUNDS AND METHODS OF MAKING AND USING SAME | Pfizer Inc (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20180360791-A1 | FATTY ACID MONOGLYCERIDE COMPOSITIONS | Steifel Research Australia PTY, Ltd | 2018-12-20 | — | — | US | disclosed |
| WO-2018073790-A1 | THERAPEUTIC PARTICLES WITH PEPTIDE BORONIC ACID OR BORONATE ESTER COMPOUNDS AND METHODS OF MAKING AND USING SAME | PFIZER INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| CN-102368904-B | Glycerol monofatty acid ester composition | STIEFEL LABORATORIES | 2014-03-26 | — | — | CN | disclosed |
| EP-2408299-B1 | FATTY ACID MONOGLYCERIDE COMPOSITIONS | STIEFEL LABORATORIES (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2408299-A1 | FATTY ACID MONOGLYCERIDE COMPOSITIONS | Stiefel Laboratories, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110305646-A1 | FATTY ACID MONOGLYCERIDE COMPOSITIONS | STIEFEL LABORATORIES, INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2010108060-A1 | FATTY ACID MONOGLYCERIDE COMPOSITIONS | STIEFEL LABORATORIES, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305646-A1 | FATTY ACID MONOGLYCERIDE COMPOSITIONS | MGLL, DGAT1, AGPAT5 | CES2 1288/4885MEN1 443/4885KMT2A 1345/4885 |
| US-20180360791-A1 | FATTY ACID MONOGLYCERIDE COMPOSITIONS | MGLL, DGAT1, DGAT2 | CES2 1272/4885MEN1 512/4885KMT2A 1471/4885 |
| US-20200261596-A1 | Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same | BCL6, BCL3, BCL9 | CES2 3078/4885MEN1 62/4885KMT2A 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.